Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Completed · Phase 1

Conditions studied: Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia

In brief

The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.

Key facts

Study ID

NCT00251368

Run by

Dana-Farber Cancer Institute

People needed

52

Starts

1995-01-01

Expected to finish

2007-09-01

Last updated by the study team

2011-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase
• Central venous access
• ECOG performance status of less than or equal to 2
• Bilirubin < 1.3
• SGOT < 2 x ULN
• Alkaline phosphatase < 2 x ULN
• Creatinine < 1.5

You may not qualify if…

• Undergone bone marrow transplantation
• Uncontrolled infection
• Other active malignancy
• HIV positivity
• Serious medical or psychiatric illness
• Pregnancy

Where it is running

• Massachusetts General Hosptial — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.